

COMPENDIA TRANSPARENCY TRACKING FORM FOR ONCOLOGY OFF-LABEL USES DERIVED FROM GUIDELINES

DATE: June 6, 2025

DRUG NAME: Acetylcysteine

OFF-LABEL USE: Chemotherapy-induced peripheral neuropathy, in patients with cancer undergoing treatment with neurotoxic agents;
Prophylaxis

| COMPENDIA TRANSPARENCY REQUIREMENTS | |
|-------------------------------------|--|
| 1 | Provide criteria used to evaluate/prioritize the request (therapy) |
| 2 | Disclose evidentiary materials reviewed or considered |
| 3 | Provide names of individuals who have substantively participated in the review or disposition of the request and disclose their potential direct or indirect conflicts of interest |
| 4 | Provide meeting minutes and records of votes for disposition of the request (therapy) |

EVALUATION/PRIORITIZATION CRITERIA: C, *to meet requirement 1(C, L)

| CODE | EVALUATION/PRIORITIZATION CRITERIA |
|------|---|
| A | Treatment represents an established standard of care or significant advance over current therapies |
| C | Cancer or cancer-related condition |
| E | Quantity and robustness of evidence for use support consideration |
| L | Limited alternative therapies exist for condition of interest |
| P | Pediatric condition |
| R | Rare disease |
| S | Serious , life-threatening condition |

Note: a combination of codes may be applied to fully reflect points of consideration [eg, therapy may represent an advance in the treatment of a life-threatening condition with limited treatment alternatives (ASL)]

EVIDENCE CONSIDERED:

*to meet requirements 2 and 4

| CITATION | LITERATURE CODE |
|---|-----------------|
| Loprinzi CL, Lacchetti C, Bleeker J, Cavaletti G, Chauhan C, Hertz DL, Kelley MR, Lavino A, Lustberg MB, Paice JA, Schneider BP, Lavoie Smith EM, Smith ML, Smith TJ, Wagner-Johnston N, Hershman DL. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. J Clin Oncol. 2020 Oct 1;38(28):3325-3348. doi: 10.1200/JCO.20.01399. Epub 2020 Jul 14. PMID: 32663120. | S |
| | |

Literature evaluation codes: S = Literature selected; 1 = Literature rejected = Topic not suitable for scope of content; 2 = Literature rejected = Does not add clinically significant new information; 3 = Literature rejected = Methodology flawed/Methodology limited and unacceptable; 4 = Other (review article, letter, commentary, or editorial)

CONTRIBUTORS:

*to meet requirement 3

| PACKET PREPARATION | DISCLOSURES |
|------------------------|-------------|
| Stacy LaClaire, PharmD | None |
| Deanna Rossi, PharmD | None |
| | |
| | |
| | |

ASSIGNMENT OF RATINGS:

*to meet requirement 4

| | EFFICACY | STRENGTH OF RECOMMENDATION | STRENGTH OF EVIDENCE |
|---------------------|-------------------------------------|-----------------------------|----------------------|
| MERATIVE MICROMEDEX | Class IIb- Evidence is Inconclusive | Class III – Not Recommended | B |
| | | | |
| | | | |
| | | | |